Hybrigenics Wins a USD 2.1 Million Yeast Two-Hybrid Contract
News Sep 02, 2009
Hybrigenics announces the signature of a 3-year research services agreement worth USD 2.1 million with an US multinational life sciences company.
Under the agreement, Hybrigenics will build specific cDNA libraries from the living organisms of interest to the client company, perform yeast two-hybrid (Y2H) screens on demand, and compile exclusive bioinformatics databases of newly identified protein interactions.
The results will be visualized and exploited with Hybrigenics' highly sophisticated bioinformatics tools, such as its PIM-Rider software. As part of this 3-year commitment of USD 700,000 per year, Hybrigenics will designate dedicated program managers and ensure top priority completion of the Y2H screens requested by the client company.
"This contract shows that, in addition to its unique expertise and technology, Hybrigenics can also offer well-designed externalization contract conditions that can convince major life sciences organizations to work with Hybrigenics for reasons of speed, efficiency and cost-effectiveness against the background of the current economic environment that is driving rationalization," said Remi Delansorne, Hybrigenics' CEO.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.